Recent in vivo studies in mice showed that lovastatin can overcome gefitinib resistance in NSCLC cells harbouring a K-Ras mutation via inhibition of the MAPK and PI3K/AKT pathways55. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.